AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Akebia Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.68+0.01 (+1.51%)
Close on Oct 19, 2026
- Market cap
- $183.36M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
39.7%
110M of 277M shares
Institutional holders
170
37 new, 36 sold out
Net institutional buying
8M
In Q2 2026
Insider trades, 12 months
1 buys · 16 sales
Net sold $876.37K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 19,219,819 | 7.20% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AKBA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 19,986,374 | 7.21% | $22.78M | +1,293,078 | 0.00% |
| Vanguard Capital Management LLC | 11,322,143 | 4.09% | $12.91M | +155,433 | 0.00% |
| Aqr Capital Management LLC | 9,151,524 | 3.30% | $10.43M | +7,358,904 | 0.00% |
| Geode Capital Management, LLC | 6,727,302 | 2.43% | $7.67M | +275,050 | 0.00% |
| State Street Corp | 5,390,853 | 1.95% | $6.15M | −6,223,153 | 0.00% |
| Jacobs Levy Equity Management, Inc | 4,273,026 | 1.54% | $4.87M | +3,843,357 | 0.02% |
| Acadian Asset Management LLC | 4,004,867 | 1.45% | $4.56K | +2,627,799 | 0.01% |
| Nantahala Capital Management, LLC | 4,000,000 | 1.44% | $4.56M | +2,000,000 | 0.08% |
| Goldman Sachs Group Inc | 3,689,167 | 1.33% | $4.21M | +86,340 | 0.00% |
| Millennium Management LLC | 3,196,605 | 1.15% | $3.64M | +811,892 | 0.00% |
| Vanguard Portfolio Management LLC | 2,533,977 | 0.91% | $2.89M | +318,536 | 0.00% |
| Two Sigma Investments, LP | 2,436,673 | 0.88% | $2.78M | +1,138,872 | 0.00% |
| Charles Schwab Investment Management Inc | 2,300,438 | 0.83% | $2.62M | +284,861 | 0.00% |
| Northern Trust Corp | 2,160,365 | 0.78% | $2.46M | +214,779 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,908,797 | 0.69% | $2.18M | +129,496 | 0.00% |
| FMR LLC | 1,871,059 | 0.68% | $2.13M | +535,731 | 0.00% |
| Qube Research & Technologies Ltd | 1,779,707 | 0.64% | $2.03M | −615,508 | 0.00% |
| Citadel Advisors LLC | 1,717,659 | 0.62% | $1.96M | +327,592 | 0.00% |
| UBS Group AG | 1,374,950 | 0.50% | $1.57M | +605,479 | 0.00% |
| Renaissance Technologies LLC | 1,223,963 | 0.44% | $1.40M | −609,165 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 170 | 110M | 39.7% | 37 / 69 | 33 / 36 | 29M | 20M |
| Q1 2026 | 171 | 102M | 36.7% | 37 / 41 | 53 / 29 | 24M | 24M |
| Q4 2025 | 166 | 118M | 42.7% | 23 / 63 | 48 / 32 | 18M | 25M |
| Q3 2025 | 177 | 125M | 45.0% | 40 / 67 | 39 / 18 | 28M | 12M |
| Q2 2025 | 157 | 108M | 39.1% | 32 / 77 | 23 / 18 | 28M | 15M |
| Q1 2025 | 143 | 96M | 34.5% | 30 / 63 | 26 / 5 | 35M | 1M |
| Q4 2024 | 121 | 68M | 24.6% | 24 / 47 | 19 / 15 | 11M | 2M |
| Q3 2024 | 114 | 60M | 21.5% | 27 / 31 | 25 / 15 | 21M | 6M |
| Q2 2024 | 103 | 56M | 20.3% | 23 / 31 | 23 / 32 | 19M | 21M |
| Q1 2024 | 114 | 59M | 21.2% | 40 / 27 | 24 / 13 | 11M | 8M |
| Q4 2023 | 87 | 55M | 20.0% | 15 / 23 | 20 / 4 | 7M | 2M |
| Q3 2023 | 76 | 51M | 18.4% | 7 / 19 | 21 / 10 | 3M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of AKBA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 7,912,283 | 2.86% | $9.02M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 6,792,653 | 2.45% | $7.74M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 3,164,884 | 1.14% | $3.61M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,807,664 | 1.01% | $3.71M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 2,169,896 | 0.78% | $2.47M | 0.02% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 1,638,117 | 0.59% | $1.87M | 0.03% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,397,714 | 0.50% | $1.43M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 1,298,780 | 0.47% | $1.32M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,262,655 | 0.46% | $1.29M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 868,716 | 0.31% | $990.34K | 0.07% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 751,608 | 0.27% | $766.64K | 0.00% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 631,828 | 0.23% | $834.01K | 0.01% | Jul 31, 2026 |
| iShares U.S. Small-Cap Equity Factor ETF | 613,144 | 0.22% | $809.35K | 0.02% | Jul 31, 2026 |
| AQR Small Cap Multi-Style Fund | 566,557 | 0.20% | $645.87K | 0.17% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 466,701 | 0.17% | $476.04K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John P. Butler | CEO and President, Director | 3,878,492 | 1.40% | Aug 10, 2026 |
| Erik Ostrowski | SVP, CFO, CBO & Treasurer | 616,616 | 0.22% | Jul 1, 2026 |
| Steven Keith Burke | SVP, Chief Medical Officer | 948,432 | 0.34% | Feb 4, 2026 |
| Nicholas Grund | Chief Commercial Officer | 561,750 | 0.20% | Feb 4, 2026 |
| Richard C. Malabre | SVP, Chief Accounting Officer | 312,772 | 0.11% | Feb 4, 2026 |
| Carolyn M. Rucci | SVP, Chief Legal Officer | 588,378 | 0.21% | Feb 4, 2026 |
| Leanne M. Zumwalt | Director | 145,100 | 0.05% | Jun 22, 2026 |
| Cynthia Smith | Director | 196,633 | 0.07% | Jun 22, 2026 |
| Adrian Adams | Director | 236,200 | 0.09% | Jun 22, 2026 |
| Michael W. Rogers | Director | 197,429 | 0.07% | Jun 22, 2026 |
| Myles Wolf | Director | 169,081 | 0.06% | Jun 22, 2026 |
| Ron Frieson | Director | 165,200 | 0.06% | Jun 22, 2026 |
| Philip J. Vickers | Director | – | – | Apr 3, 2026 |
| Steven C. Gilman | Director | 152,830 | 0.06% | Jun 11, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John P. Butler CEO and President, Director | Aug 6, 2026 | Option exercise | +350,000 | $0.63 | $220.50K | 3,718,564 |
| Erik Ostrowski SVP, CFO, CBO & Treasurer | Jun 29, 2026 | Sale(10b5-1 plan) | −56,019 | $1.11 | $62.18K | 616,616 |
| Adrian Adams Director | Jun 17, 2026 | Award | +35,700 | – | – | 236,200 |
| Cynthia Smith Director | Jun 17, 2026 | Award | +35,700 | – | – | 196,633 |
| Leanne M. Zumwalt Director | Jun 17, 2026 | Award | +35,700 | – | – | 145,100 |
| Ron Frieson Director | Jun 17, 2026 | Award | +35,700 | – | – | 165,200 |
| Michael W. Rogers Director | Jun 17, 2026 | Award | +35,700 | – | – | 197,429 |
| Myles Wolf Director | Jun 17, 2026 | Award | +35,700 | – | – | 169,081 |
| John P. Butler CEO and President, Director | Mar 4, 2026 | Buy | +69,270 | $1.25 | $86.59K | 3,367,064 |
| Richard C. Malabre SVP, Chief Accounting Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −36,142 | $1.39 | $50.24K | 312,772 |
| Richard C. Malabre SVP, Chief Accounting Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −13,382 | $1.39 | $18.60K | 299,390 |
| Nicholas Grund Chief Commercial Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −31,244 | $1.39 | $43.43K | 561,750 |
| Nicholas Grund Chief Commercial Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −53,585 | $1.39 | $74.48K | 592,994 |
| Steven Keith Burke SVP, Chief Medical Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −20,701 | $1.39 | $28.77K | 948,432 |
| Steven Keith Burke SVP, Chief Medical Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −21,582 | $1.39 | $30.00K | 994,508 |
| Steven Keith Burke SVP, Chief Medical Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −25,375 | $1.39 | $35.27K | 969,133 |
| John P. Butler CEO and President, Director | Feb 2, 2026 | Sale(10b5-1 plan) | −46,660 | $1.39 | $64.86K | 3,417,189 |
| John P. Butler CEO and President, Director | Feb 2, 2026 | Sale(10b5-1 plan) | −96,065 | $1.39 | $133.53K | 3,321,124 |
| John P. Butler CEO and President, Director | Feb 2, 2026 | Sale(10b5-1 plan) | −114,891 | $1.39 | $159.70K | 3,206,233 |
| John P. Butler CEO and President, Director | Feb 2, 2026 | Sale(10b5-1 plan) | −83,689 | $1.39 | $116.33K | 3,297,794 |
| John P. Butler CEO and President, Director | Feb 2, 2026 | Award | +175,250 | $1.41 | $247.10K | 3,381,483 |
| Erik Ostrowski SVP, CFO, CBO & Treasurer | Feb 2, 2026 | Sale(10b5-1 plan) | −34,951 | $1.39 | $48.58K | 672,635 |
| Carolyn M. Rucci SVP, Chief Legal Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −27,544 | $1.39 | $38.29K | 588,378 |
| Carolyn M. Rucci SVP, Chief Legal Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −25,382 | $1.39 | $35.28K | 615,922 |
| Carolyn M. Rucci SVP, Chief Legal Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −16,846 | $1.39 | $23.42K | 641,304 |
| Richard C. Malabre SVP, Chief Accounting Officer | Jan 30, 2026 | Award | +79,000 | – | – | 348,914 |
| John P. Butler CEO and President, Director | Jan 30, 2026 | Award | +743,000 | – | – | 3,463,849 |
| Steven Keith Burke SVP, Chief Medical Officer | Jan 30, 2026 | Award | +204,000 | – | – | 1,016,090 |
| Nicholas Grund Chief Commercial Officer | Jan 30, 2026 | Award | +204,000 | – | – | 646,579 |
| Carolyn M. Rucci SVP, Chief Legal Officer | Jan 30, 2026 | Award | +190,000 | – | – | 658,150 |
| Erik Ostrowski SVP, CFO, CBO & Treasurer | Jan 30, 2026 | Award | +204,000 | – | – | 707,586 |
| Erik Ostrowski SVP, CFO, CBO & Treasurer | Jun 30, 2025 | Sale(10b5-1 plan) | −41,314 | $3.67 | $151.62K | 503,586 |
| Michael W. Rogers Director | Jun 10, 2025 | Award | +35,700 | – | – | 161,729 |
| Ron Frieson Director | Jun 10, 2025 | Award | +35,700 | – | – | 129,500 |
| Steven C. Gilman Director | Jun 10, 2025 | Award | +35,700 | – | – | 152,830 |
| Leanne M. Zumwalt Director | Jun 10, 2025 | Award | +35,700 | – | – | 109,400 |
| Cynthia Smith Director | Jun 10, 2025 | Award | +35,700 | – | – | 160,933 |
| Myles Wolf Director | Jun 10, 2025 | Award | +35,700 | – | – | 133,381 |
| Adrian Adams Director | Jun 10, 2025 | Award | +35,700 | – | – | 200,500 |
| Richard C. Malabre SVP, Chief Accounting Officer | Jun 9, 2025 | Option exercise | +15,000 | $1.68 | $25.20K | 281,914 |
| Richard C. Malabre SVP, Chief Accounting Officer | Jun 9, 2025 | Sale(10b5-1 plan) | −15,000 | $4.01 | $60.15K | 266,914 |
| Richard C. Malabre SVP, Chief Accounting Officer | Jun 4, 2025 | Sale(10b5-1 plan) | −13,334 | $3.53 | $47.07K | 266,914 |
| John P. Butler CEO and President, Director | Mar 3, 2025 | Sale(10b5-1 plan) | −46,409 | $1.83 | $84.93K | 2,557,921 |
| Steven Keith Burke SVP, Chief Medical Officer | Mar 3, 2025 | Sale(10b5-1 plan) | −7,144 | $1.83 | $13.07K | 809,090 |
| Richard C. Malabre SVP, Chief Accounting Officer | Feb 3, 2025 | Sale(10b5-1 plan) | −30,202 | $2.10 | $63.42K | 280,248 |
| Nicholas Grund Chief Commercial Officer | Feb 3, 2025 | Sale(10b5-1 plan) | −55,621 | $2.10 | $116.80K | 442,579 |
| Steven Keith Burke SVP, Chief Medical Officer | Feb 3, 2025 | Sale(10b5-1 plan) | −27,236 | $2.10 | $57.20K | 816,234 |
| Steven Keith Burke SVP, Chief Medical Officer | Feb 3, 2025 | Sale(10b5-1 plan) | −23,270 | $2.10 | $48.87K | 843,470 |
| John P. Butler CEO and President, Director | Feb 3, 2025 | Sale(10b5-1 plan) | −97,982 | $2.10 | $205.76K | 2,604,330 |
| John P. Butler CEO and President, Director | Feb 3, 2025 | Sale(10b5-1 plan) | −46,268 | $2.10 | $97.16K | 2,702,312 |
| Richard C. Malabre SVP, Chief Accounting Officer | Jan 31, 2025 | Award | +85,000 | – | – | 310,450 |
| Erik Ostrowski SVP, CFO, CBO & Treasurer | Jan 31, 2025 | Award | +194,900 | – | – | 544,900 |
| Nicholas Grund Chief Commercial Officer | Jan 31, 2025 | Award | +194,900 | – | – | 498,200 |
| Steven Keith Burke SVP, Chief Medical Officer | Jan 31, 2025 | Award | +194,900 | – | – | 866,740 |
| John P. Butler CEO and President, Director | Jan 31, 2025 | Award | +701,000 | – | – | 2,748,580 |
| Ron Frieson Director | Jan 17, 2025 | Option exercise | +20,100 | $0.45 | $9.05K | 93,800 |
| Erik Ostrowski SVP, CFO, CBO & Treasurer | Jun 28, 2024 | Award | +350,000 | – | – | 350,000 |
| Steven C. Gilman Director | Jun 6, 2024 | Award | +30,000 | – | – | 117,130 |
| Ron Frieson Director | Jun 6, 2024 | Award | +30,000 | – | – | 73,700 |
| Leanne M. Zumwalt Director | Jun 6, 2024 | Award | +30,000 | – | – | 73,700 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Erik Ostrowski Officer | Jun 29, 2026 | 56,019 | $62.22K | Jun 29, 2026 | Vesting of restricted stock unit |
| Carolyn M. Rucci Officer | Feb 2, 2026 | 69,772 | $97.30K | Feb 2, 2026 | Restricted Stock |
| John P. Butler Officer | Feb 2, 2026 | 341,305 | $475.95K | Feb 2, 2026 | Restricted Stock |
| Steven Keith Burke Officer | Feb 2, 2026 | 67,658 | $94.35K | Feb 2, 2026 | Restricted Stock |
| Nicholas Grund Officer | Feb 2, 2026 | 84,829 | $118.29K | Feb 2, 2026 | Restricted Stock |
| Erik Ostrowski Officer | Feb 2, 2026 | 34,951 | $48.74K | Feb 2, 2026 | Restricted Stock |
| Erik Ostrowski Officer | Jun 30, 2025 | 41,314 | $151.62K | Jun 30, 2025 | Restricted Stock |
| Steven Keith Burke Officer | Mar 3, 2025 | 7,144 | $13.09K | Mar 3, 2025 | Restricted Stock |
| John P. Butler Officer, Director | Mar 3, 2025 | 46,409 | $85.01K | Mar 3, 2025 | Restricted Stock |
| Steven Keith Burke Officer | Feb 3, 2025 | 50,506 | $106.30K | Feb 3, 2025 | Restricted Stock |
| John P. Butler Officer, Director | Feb 3, 2025 | 144,250 | $303.59K | Feb 3, 2025 | Restricted Stock |
| Nicholas Grund Officer | Feb 3, 2025 | 55,621 | $117.06K | Feb 3, 2025 | Restricted Stock |
| Nicole R. Hadas Officer | May 13, 2024 | 12,016 | $15.11K | May 13, 2024 | Restricted Stock |
| Michel Dahan Officer | May 13, 2024 | 34,840 | $43.82K | May 13, 2024 | Restricted Stock |
| Michel Dahan Officer | Feb 29, 2024 | 8,661 | $13.65K | Feb 29, 2024 | Restricted Stock |